Skip to content

The neural circuit mechanism of emotional regulation in late-life depression by mindfulness-based cognitive therapy

The neural circuit mechanism of emotional regulation in late-life depression by mindfulness-based cognitive therapy

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2500096686
Enrollment
Unknown
Registered
2025-02-04
Start date
2025-02-04
Completion date
Unknown
Last updated
2025-02-10

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Late-life depression

Interventions

Mindfulness-based cognitive therapy group:The Mindfulness-Based Cognitive Therapy (MBCT) group will undergo a 4-week intervention, using a combined online and offline mindfulness treatment program. Th
Health education group:The Health Education group will undergo a 4-week intervention, consisting of 8 themed health education sessions. The courses cover common diseases and health care knowledge in t
Coronary Heart Disease
Diabetes Mellitus
Hypertension
Cerebrovascular Disease
Osteoarthritis
Deme

Sponsors

Peking University Sixth Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
60 Years to No maximum

Inclusion criteria

Inclusion criteria: a. Age>= 60 years, gender unrestricted. b. Patients with a past or current diagnosis of unipolar depression (single or recurrent episodes) according to the ICD-10 criteria, confirmed by two attending physicians. c. A score of >= 14 on the 24-item Hamilton Depression Rating Scale (HDRS), with stable pharmacological treatment for at least two weeks. d. Patients are able to understand and cooperate with the treatment. e. Informed consent form has been signed.

Exclusion criteria

Exclusion criteria: a. Patients with severe suicidal risk. b. Patients with a Mini-Mental State Examination (MMSE) score of less than 24. c. Patients who meet the diagnostic criteria for any other mental disorder in the ICD-10, in addition to depression. d. Patients with severe somatic diseases resulting in impaired function of vital organs, or who cannot complete the treatment requirements due to other somatic diseases. e. Patients who are simultaneously receiving other forms of psychotherapy or participating in other therapeutic studies. f. Patients using central nervous system stimulants, antipsychotics, anti-dementia medications, or anti-Parkinson’s drugs concurrently. g. Patients who have received electroconvulsive therapy (ECT) with or without convulsions, transcranial magnetic stimulation (TMS), or deep brain stimulation (DBS) within the past 3 months.

Design outcomes

Primary

MeasureTime frame
Depression severity score;Anxiety severity score;Screening for psychological and mental health;Assessment of sleep quality;Assessment of overall life satisfaction;Assessment of health-related quality of life;Cognitive function score;Neural activity and functional state of the brain;Electroencephalographic activity;Cardiac function;Pulmonary function;The composition of blood cells and basic functional status;Immune indicators;

Countries

China

Contacts

Public ContactSun Xinyu

Peking University Sixth Hospital

sunxinyu@bjmu.edu.cn+86 139 1097 9775

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026